Dr. Rabinder Buttar | President, CEO & Founder
Dr Buttar’s clinical experience spans more than three decades within major pharmaceutical companies and within her own organization, Clintec.
Dr Rabinder Buttar, President, CEO & Founder of Clintec International, an IQVIA company, a global CRO which she founded over 22 years ago. Her experience includes 30 years in academia (Strathclyde, Glasgow, and Reading) and the clinical research industry, including positions within Pfizer (Wyeth), GSK (Wellcome) and Astellas (Fujisawa), as well as growing her own CRO, Clintec. Since its inception, Clintec has organically grown globally, with large teams in over 50 countries. Furthermore, Dr Buttar is successfully behind and directly contributed to bringing 3 blockbuster drugs to the market, two of which were Clintec projects.
In 2014, Dr Buttar was listed by the British Science Council as one of top 10 practising entrepreneurial scientists in Britain and has previously been named as one of Britain’s top 100 entrepreneurial women (Real Business). During 2015, Dr Buttar was inducted into Strathclyde’s Academy of Distinguished Entrepreneurs, and has received many prestigious awards such as Ernst & Young ‘Scottish Entrepreneur of the Year’, the Institute of Directors ‘Director of the Year’ and Business Woman of the Year (People Make Glasgow); all her accolades recognize Dr Buttar’s success in global business, entrepreneurship, and leadership.
Clintec itself has also received numerous recognitions, including the Queen’s Award for Enterprise International Trades in 2011 & 2017 and recent awards such as Scale-Up Business of the Year, 2016 & 2018 at the Minority Supplier Development Awards, Ranked 84th at the Sunday Times HSBC International Track 200 2018 and Leadership Award at Scotland’s Life Science Award 2019.
Dr Buttar is a PhD immunologist from Strathclyde with a BSc in Biochemistry from Glasgow University, certificate in Management from Reading University and Honorary Doctorate from University of West of Scotland. Clintec has given her the opportunity to combine her interest in these areas and build the most geographically diverse clinical research business in the world.